Application of composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines

An anti-epileptic drug and ginsenoside technology are applied in the field of medicine to achieve the effects of enhancing effect and curative effect, reducing dosage and reducing adverse drug reactions.

Inactive Publication Date: 2016-09-28
欧阳冬生 +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, so far, there has been no anti-epileptic research on ginsenoside C-K at home and abroad, and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines
  • Application of composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines
  • Application of composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 The composition of ginsenoside C-K and lamotrigine interferes with the acute epilepsy model induced by lithium chloride-pilocarpine

[0015] 1. Experimental method

[0016] 1.1 Dose Design and Grouping

[0017] The experiment was divided into normal control group, epilepsy model group, lamotrigine group (20mg / kg), ginsenoside C-K group (160mg / kg), ginsenoside C-K (160mg / kg) combined with lamotrigine group (20mg / kg )Group. (See Table 1).

[0018] Table 1 Experimental grouping and dose design

[0019]

[0020] 1.2 Experimental steps

[0021] 50 SPF grade healthy male SD rats (body weight 180-220g) were randomly divided into normal control group (group A), epilepsy model group (group B), lamotrigine group (group C), ginsenoside C-K group ( D group), ginsenoside C-K+lamotrigine group (E group), 10 rats in each group. Lamotrigine or ginsenosides C-K were prepared with 0.5% CMC-Na to the corresponding concentration according to the dose before the daily exp...

Embodiment 2

[0031] Example 2 The composition of ginsenoside C-K and lamotrigine interferes with the acute epilepsy model induced by pentylenetetrazol

[0032] 1. Experimental method

[0033] 1.1 Dose Design and Grouping

[0034] The experiment was divided into normal control group, epilepsy model group, lamotrigine group (20mg / kg), ginsenoside C-K group (160mg / kg), ginsenoside C-K (160mg / kg) combined with lamotrigine group (20mg / kg )Group. (See Table 3).

[0035] Table 3 Experimental grouping and dose design

[0036]

[0037] 1.2 Experimental steps

[0038] 50 SPF grade healthy male SD rats (body weight 180-220g) were randomly divided into normal control group (group A), epilepsy model group (group B), lamotrigine group (group C), ginsenoside C-K group ( D group), ginsenoside C-K+lamotrigine group (E group), 10 rats in each group. Lamotrigine or ginsenosides C-K were prepared with 0.5% CMC-Na to the corresponding concentration according to the dose before the daily experiment, an...

Embodiment 3

[0048] Example 3 The composition of ginsenoside C-K and lamotrigine in different mass ratios interferes with the acute epilepsy model induced by pentylenetetrazol

[0049] 1. Experimental method

[0050] 1.1 Dose Design and Grouping

[0051] The experiment was divided into normal control group, epilepsy model group and compound intervention group. (See Table 4).

[0052] Table 4 group administration

[0053]

[0054] 1.2 Experimental steps

[0055] 70 SPF grade healthy male SD rats (body weight 180-220g), were randomly divided into normal control group (group A), epilepsy model group (group B), composition intervention 1, 2, 3, 4, 5 groups (group C) , D, E, F, G groups), 10 rats in each group. Before the daily experiment, lamotrigine, ginsenosides C-K and the composition were formulated with 0.5% CMC-Na according to the dose to the corresponding concentration, and they were prepared and used immediately. The body weight of the rats was weighed before administration ev...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel medicines and application, and particularly provides application of a composition of ginsenoside C-K and lamotrigine in preparation of anti-epilepsy medicines. Animal experiments prove that the composition of ginsenoside C-K and lamotrigine can be used for remarkably prolonging the incubation period of epilepsy, reducing the attack strength of epilepsy, shortening the duration of epilepsy and reducing the weight loss after attack, and indicate that the composition of ginsenoside C-K and lamotrigine can be used for relieving or controlling attack of epilepsy and inhibiting occurrence and development of epilepsy, and adverse medicine response caused by lamotrigine can be alleviated by reducing the dosage of lamotrigine.

Description

technical field [0001] The invention belongs to the technical field of medicine, specifically relates to the field of a new pharmaceutical composition and its new application, in particular to the new application of the composition of ginsenoside C-K and lamotrigine in the preparation of antiepileptic drugs. Background technique [0002] Epilepsy is a brain disorder characterized by the persistence of permanent changes in the brain that produce seizures, with corresponding neurobiological, cognitive, psychological, and sociological consequences. There are about 70 million epilepsy patients worldwide, of which more than 90% are in low- and middle-income countries, and about 2.4 million new diagnoses are made each year. According to statistics from the my country Anti-Epileptic Association, there are about 10 million epileptic patients in China, and more than 450,000 new epileptic patients are added every year, of which about two-thirds are in rural areas, and the treatment ga...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7032A61K31/53A61P25/08
CPCA61K31/53A61K31/7032A61K2300/00
Inventor 曾祥昌欧阳冬生胡凯陈露露周露萍罗伟王欣桐高青李晓辉周宏灏
Owner 欧阳冬生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap